Cell-sizing method for high-accuracy feline lymphoma characterisation in veterinary sciences

August 14, 2024

ImpriMed has unveiled a new method that effectively links cell size categories for feline lymphomas directly to cancer survival rates

--

ImpriMed, a leading precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, has announced the publication of its groundbreaking research on a novel cell-sizing method for feline lymphomas in veterinary sciences.

This study marks a significant advancement in the diagnostic support and prognosis of feline lymphomas. By improving the precision of cell size assessment, ImpriMed’s method can potentially transform veterinary oncology, providing more reliable prognostic insights, and enhancing treatment planning and patient outcomes.

ImpriMed’s study, titled “Prognostic utility of the flow cytometry and clonality analysis results for feline lymphomas,” presents flow cytometry and clonality evaluation as reliable methods for characterising feline lymphomas. Study findings highlight the effectiveness of ImpriMed’s flow cytometry-based approach in distinguishing between small, medium and large cell sizes, which correlates with patient survival rates. Additionally, this system achieved an impressive 82 to 90 percent concordance with the gold standard of cytology.

“We are thrilled to share our breakthrough findings with the veterinary community,” said Sungwon Lim, ImpriMed’s CEO and co-founder. “Our innovative cell-sizing method is a significant advancement in the fight against feline lymphomas, equipping veterinarians nationwide with enhanced tools for accurate diagnosis and effective treatment of this challenging disease.”  

Although flow cytometry is widely used to identify and characterise lymphomas in dogs and humans, its application in cats has been relatively unexplored. Lymphoma is one of the most common cancers in cats, accounting for nearly 30 percent of all feline cancers. ImpriMed’s method uniquely leverages flow cytometry to assess feline neoplastic cells across size categories. This detailed categorisation is crucial for prognosis and significantly impacts treatment decisions.

Study highlights

  • Objective: to investigate the utility of flow cytometry and clonality analysis via PCR for antigen receptor rearrangement (PARR) in characterising feline lymphoma and predicting prognosis
  • Method: fine needle aspirates and/or blood samples from 438 feline patients were analysed. Flow cytometry parameters, particularly forward scatter thresholds, were optimised for cell size categorisation
  • Results:
    • The novel cell-sizing method showed 82 percent concordance with cytological sizing in a training set and 90 percent concordance in an independent test set
    • Expanded research with more patients showed significant survival differences. Cats with small-cell lymphomas survived the longest (median 312 days), followed by medium-cell (median 189 days) and large-cell with a median survival time of 81 days
    • Lymphoma subtypes defined by flow cytometry and PARR demonstrated significant survival differences, emphasising the system’s potential prognostic utility

This milestone achievement demonstrates ImpriMed’s commitment to addressing the unmet needs of feline cancer patients. Their novel technique increases the resolution of cell-sizing determinations, the most comprehensive evaluation of medium-cell survival rates to date.

ImpriMed’s publication lays the groundwork for a forthcoming study of AI-driven prognostication for feline lymphoma that aims to further revolutionise predictive analytics for individualised patient treatment strategies.

In the News

How Artificial Intelligence Is Revolutionising Cancer Care for Pets

Pets Magazine
Learn More →

Artificial Intelligence Takes on Cancer: The Only AI Dr. Karyn Doesn’t Hate

Dogster
Learn More →

Comparative Oncology: Advances in Cancer Care from Pets to Humans

Pharmacy Times
Learn More →

Cancer Treatment Gets Personal: How Artificial Intelligence Is Taking the Guesswork Out of Common Canine Cancers

Dogster
Learn More →

Ilona Holcomb on How ImpriMed’s AI is Transforming Cancer Treatment for Pets and Humans

Biopharma Boardroom
Learn More →

From Dogs to Humans: AI-Powered Drug Response Prediction Technology Demonstrates Improved Clinical Outcomes in Oncology

Pharmacy Times
Learn More →

ImpriMed unveils cancer treatment forecast technology

MobiHealthNews
Learn More →

New research evaluates flow cytometry and PARR as diagnostic support for feline lymphoma

American Animal Hospital Association NEWStat®
Learn More →

Flow cytometry and clonality evaluation are effective for characterizing feline lymphoma

DVM360
Learn More →

ImpriMed: Providing Personalized Medicine For Pets With Blood Cancer Diseases In A $1+ Billion Market

Pulse 2.0
Learn More →

New AI Tool Guides Canine Cancer Treatment

Today's Veterinary Business
Learn More →

Artificial intelligence poised to transform veterinary care

AVMA News
Learn More →

New AI service offers personalized drug response predictions for canine patients with cancer

DVM360
Learn More →

Dog cancer treatment ImpriMed aims to expand its AI technology into human oncology

TechCrunch
Learn More →

ImpriMed’s Transformative, Personal Approach to Canine Cancer Treatment

USA Today
Learn More →

Data Science Can Markedly Improve Cancer Treatment Outcomes — ImpriMed Shows You How

Innovative Veterinary Care Journal
Learn More →

How ImpriMed Can Help Increase Cancer Remissions, Grow Your Reputation and Level Up Your Revenue

Innovative Veterinary Care Journal
Learn More →

ImpriMed: A Breath of Fresh Air for Traditionally Onerous Cancer Treatment Journeys

Innovative Veterinary Care Journal
Learn More →

ImpriMed: Revolutionizing Canine Cancer Treatment with Precision and Personalization

International Business Times
Learn More →

New AI Technology From ImpriMed Helps Improve Cancer Treatment Success Rates in Your Practice…and Fosters Better Relationships

Innovative Veterinary Care Journal
Learn More →

The latest and greatest in canine oncology treatment

DVM360
Learn More →

Get Rid of Your Cancer Treatment Frustrations

Innovative Veterinary Care Journal
Learn More →

Meet the 7 startups Mayo Clinic just welcomed to its AI accelerator

MedCity News
Learn More →

Be sure to improve your cancer treatment outcomes

Innovative Veterinary Care Journal
Learn More →

Early leukemia and lymphoma remissions in cats and dogs

Innovative Veterinary Care Journal
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 3)

One Million by One Million
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 2)

One Million by One Million
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 1)

One Million by One Million
Learn More →

Technological advancement makes cancer treatment easier

Innovative Veterinary Care Journal
Learn More →

Novel veterinary oncologic treatments and diagnostics

dvm360
Learn More →

AI’s Computing Power Could Make Fusion Energy Practical

Lifewire
Learn More →

Don't Guess Your Pet's Condition, Treat It with ImpriMed

Startup to Follow
Learn More →

Interview with ImpriMed CEO & Co-Founder Sungwon Lim

IdeaMensch
Learn More →

This Test Might Make All The Difference When Fighting Lymphoma

Canine Cancer Alliance
Learn More →

ImpriMed: Fighting Cancer — From Dogs To Humans

Startup Thread
Learn More →

At Pear demo day, a who’s who of VCs, and plenty of fresh ideas

TechCrunch
Learn More →